These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10395323)

  • 1. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
    Sotomayor EM; Borrello I; Tubb E; Rattis FM; Bien H; Lu Z; Fein S; Schoenberger S; Levitsky HI
    Nat Med; 1999 Jul; 5(7):780-7. PubMed ID: 10395323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
    Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
    Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens.
    Chung Y; Ko SY; Ko HJ; Kang CY
    Eur J Immunol; 2005 May; 35(5):1381-90. PubMed ID: 15827964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
    Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
    Loskog A; Tötterman TH; Böhle A; Brandau S
    Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cell responses to CD40-deficient APCs: defects in proliferation and negative selection apply only with B cells as APCs.
    Ozaki ME; Coren BA; Huynh TN; Redondo DJ; Kikutani H; Webb SR
    J Immunol; 1999 Nov; 163(10):5250-6. PubMed ID: 10553046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner.
    Rodríguez-Pinto D; Moreno J
    Eur J Immunol; 2005 Apr; 35(4):1097-105. PubMed ID: 15756646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.
    Toes RE; Schoenberger SP; van der Voort EI; Offringa R; Melief CJ
    Semin Immunol; 1998 Dec; 10(6):443-8. PubMed ID: 9826577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
    Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
    Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.
    Nishimura E; Sakihama T; Setoguchi R; Tanaka K; Sakaguchi S
    Int Immunol; 2004 Aug; 16(8):1189-201. PubMed ID: 15237110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD40 is necessary for activation of naïve T cells by a dendritic cell line in vivo but not in vitro.
    Haase C; Michelsen BK; Jørgensen TN
    Scand J Immunol; 2004 Mar; 59(3):237-45. PubMed ID: 15030573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.